🇺🇸 Ceftriaxone for Injection in United States
110 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 110
Most-reported reactions
- No Adverse Event — 22 reports (20%)
- Recalled Product Administered — 20 reports (18.18%)
- Expired Product Administered — 11 reports (10%)
- Pyrexia — 11 reports (10%)
- Drug Reaction With Eosinophilia And Systemic Symptoms — 8 reports (7.27%)
- Dyspnoea — 8 reports (7.27%)
- Headache — 8 reports (7.27%)
- Hypersensitivity — 8 reports (7.27%)
- Acute Kidney Injury — 7 reports (6.36%)
- Aplastic Anaemia — 7 reports (6.36%)
Other Infectious Disease approved in United States
Frequently asked questions
Is Ceftriaxone for Injection approved in United States?
Ceftriaxone for Injection does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Ceftriaxone for Injection in United States?
The University of Queensland is the originator. The local marketing authorisation holder may differ — check the official source linked above.